SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}- 4-piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor: I. Biochemical and Pharmacological Characterization
- 1 January 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (3) , 1171-1179
- https://doi.org/10.1124/jpet.102.040162
Abstract
The biochemical and pharmacological properties of a novel antagonist of the tachykinin neurokinin 1 (NK1) receptor, SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}-4-piperidinyl)-2-methylpropanamide], were evaluated. SSR240600 inhibited the binding of radioactive substance P to tachykinin NK1 receptors in human lymphoblastic IM9 cells (Ki = 0.0061 nM), human astrocytoma U373MG cells (Ki= 0.10 nM), and human brain cortex (IC50 = 0.017 nM). It also showed subnanomolar affinity for guinea pig NK1receptors but was less potent on rat and gerbil NK1receptors. SSR240600 inhibited [Sar9,Met(O2)11]substance P-induced inositol monophosphate formation in human astrocytoma U373MG cells with an IC50 value of 0.66 nM (agonist concentration of 100 nM). It also antagonized substance P-induced contractions of isolated human small bronchi with a pIC50 value of 8.6 (agonist concentration of 100 nM). The compound was >100- to 1000-fold more selective for tachykinin NK1 receptors versus tachykinin NK2 or NK3 receptors as evaluated in binding and in vitro functional assays. In vivo antagonistic activity of SSR240600 was demonstrated on tachykinin NK1receptor-mediated hypotension in dogs (3 and 10 μg/kg i.v.), microvascular leakage (1 and 3 mg/kg i.p.), and bronchoconstriction (50 and 100 μg/kg i.v.) in guinea pigs. It also prevented citric acid-induced cough in guinea pigs (1–10 mg/kg i.p.), an animal model in which central endogenous tachykinins are suspected to play a major role. In conclusion, SSR240600 is a new, potent, and centrally active antagonist of the tachykinin NK1 receptor, able to antagonize various NK1 receptor-mediated pharmacological effects in the periphery and in the central nervous system.This publication has 40 references indexed in Scilit:
- Involvement of Tachykinin NK3 Receptors in Citric Acid–induced Cough and Bronchial Responses in Guinea PigsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonistEuropean Journal of Pharmacology, 1998
- Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factorBritish Journal of Pharmacology, 1997
- The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and coughEuropean Respiratory Journal, 1997
- Peripheral effects of three novel non-peptide tachykinin NK1 receptor antagonists in the anaesthetized ratEuropean Journal of Pharmacology, 1996
- Tachykinin Receptor Antagonists and CoughPulmonary Pharmacology, 1996
- Mechanisms of Action of Central and Peripheral Antitussive DrugsPulmonary Pharmacology, 1996
- The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonistBritish Journal of Pharmacology, 1995
- Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Antitussive effect of SR 48968, a non-peptide tachykinin NK2, receptor antagonistEuropean Journal of Pharmacology, 1993